Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
Fiche publication
Date publication
avril 2023
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Olivera PA, Lasa JS, Peretto G, Zuily S, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
In the context of an ageing inflammatory bowel disease (IBD) population, cardiovascular comorbidities become particularly relevant. Novel small molecule drugs (SMDs) for the treatment of moderate-to-severe IBD have been recently approved, including Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor (S1P) modulators. Data from rheumatoid arthritis population have raised concerns about the risk of cardiovascular events with the use of tofacitinib, which was extrapolated to other immune-mediated diseases and other JAK inhibitors. S1P receptor modulation has been associated with potential cardiovascular events, especially bradycardia and cardiac conduction abnormalities.
Référence
Aliment Pharmacol Ther. 2023 04 10;: